NCT04500600: Well-Being and Health-Related Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic

NCT04500600
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be active MD Anderson patients (visit within past 5 years)
Exclusions: 
https://ClinicalTrials.gov/show/NCT04500600

Comments are closed.

Up ↑